 |
Video: What is a Stock Split?
|
 |
Dare Bioscience, Inc. is a biopharmaceutical company committed to advancing products for women's health. XACIATO, the Co.'s U.S. Food and Drug Administration (FDA)-approved product, vaginal gel 2%, a lincosamide antibacterial indicated for the treatment of bacterial vaginosis in female patients 12 years of age and older, which is under a global license agreement with Organon. Its clinical-stage programs include Ovaprene; Sildenafil Cream, 3.6%; DARE-HRT1; DARE-VVA1; DARE-CIN; DARE-PDM1; DARE-204 and DARE-214, and DARE-FRT1 and DARE-PTB1. Its pre-clinical stage programs include DARE-LARC1, DARE-LBT, DARE-GML, DARE-RH1 and DARE-PTB2. According to our DARE split history records, Dare Bioscience has had 1 split. | |
 |

Dare Bioscience (DARE) has 1 split in our DARE split history database. The split for DARE took place on July 01, 2024. This was a 1 for 12 reverse split, meaning for each 12 shares of DARE owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 83.3333333333333 share position following the split.
When a company such as Dare Bioscience conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the DARE split history from start to finish, an original position size of 1000 shares would have turned into 83.3333333333333 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Dare Bioscience shares, starting with a $10,000 purchase of DARE, presented on a split-history-adjusted basis factoring in the complete DARE split history.

Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
07/21/2015 |
|
End date: |
07/18/2025 |
|
Start price/share: |
$51.12 |
|
End price/share: |
$2.52 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-95.07% |
|
Average Annual Total Return: |
-25.99% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$493.06 |
|
Years: |
10.00 |
|
|
 |
Date |
Ratio |
07/01/2024 | 1 for 12 |
|
 |